Salud financiera de hoja de balance de Organogenesis Holdings
Salud financiera controles de criterios 6/6
Organogenesis Holdings tiene un patrimonio de accionistas total de $263.5M y una deuda total de $63.5M, lo que sitúa su ratio deuda-patrimonio en 24.1%. Sus activos y pasivos totales son $443.2M y $179.7M respectivamente. El BAIT de Organogenesis Holdings es de $13.9M, por lo que su ratio de cobertura de intereses es de 6.7. Tiene efectivo e inversiones a corto plazo que ascienden a $89.9M.
Información clave
24.1%
Ratio deuda-patrimonio
US$63.49m
Deuda
| Ratio de cobertura de intereses | 6.7x |
| Efectivo | US$89.90m |
| Patrimonio | US$263.50m |
| Total pasivo | US$179.66m |
| Activos totales | US$443.16m |
Actualizaciones recientes sobre salud financiera
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?
Apr 10
These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well
Jan 04Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?
May 31Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?
Jan 19Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly
Sep 23Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly
Jun 10Recent updates
Why Investors Shouldn't Be Surprised By Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Low P/S
Sep 09We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope
Jun 15Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst
Jun 10Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality
May 21Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price
May 01Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?
Apr 10These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well
Jan 04Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?
May 31Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?
Jan 19Organogenesis: Finding A Spot For This Regenerative Medicines Company In My 'Bio Boom' Portfolio
Oct 18Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly
Sep 23Organogenesis gets FDA clearance for PuraPly MZ for wound healing
Aug 15Here's Why Organogenesis Holdings (NASDAQ:ORGO) Has Caught The Eye Of Investors
Jul 28Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly
Jun 10Organogenesis Holdings: What Now
May 18The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Earnings Yet
Mar 31These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well
Mar 04Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($234.2M) de ORGO superan a sus pasivos a corto plazo ($85.7M).
Pasivo a largo plazo: Los activos a corto plazo de ORGO ($234.2M) superan a sus pasivos a largo plazo ($93.9M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: ORGO tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de ORGO ha pasado de 315.3% a 24.1% en los últimos 5 años.
Cobertura de la deuda: La deuda de ORGO está bien cubierta por el flujo de caja operativo (34.5%).
Cobertura de intereses: Los pagos de intereses de la deuda de ORGO están bien cubiertos por el BAIT (6.7x cobertura).